GSK2982772 Study in Subjects With Ulcerative Colitis

Exclusion Criteria

• •Subject with diagnosis of indeterminate colitis, Crohn's Disease, infectious colitis, or ischemic colitis.
• •Subject with fulminant UC, or UC limited to the rectum (disease extent \<15 centimeters (cm) from the anal verge).
• •Subject with previous small bowel or colonic surgery(with exception of appendectomy), histological evidence of colonic dysplasia or bowel stricture.
• •Subject with colostomy, fistulae or known symptomatic stenosis of the intestine.
• •Subject with toxic megacolon.
• •Subject with positive Clostridium difficile toxin test or active/previous colonic cytomegalo virus (CMV) infection.
• •Subject with current history of suicidal ideation behavior (SIB) as measures using the Columbia Suicide Severity Rating Scale (C-SSRS) or history of attempted suicide.
• •An active infection, or a history of infections as follows:
• •Hospitalization for treatment of infection within 60 days before first dose (Day 1).
• •Currently on any suppressive therapy for a chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria).
• •Use of parenteral (intravenous (IV) or intramuscular) antibiotics (antibacterials, antivirals, antifungals, or antiparasitic agents) for an infection within 60 days before first dose.
• •A history of opportunistic infections within 1 year of screening (example: pneumocystis jirovecii, CMV pnemonitis, aspergillosis). This does not include infections that may occur in immunocompetent individuals, such as fungal nail infections or vaginal candidiasis, unless it is of an unusual severity or recurrent nature.
• •Recurrent or chronic infection or other active infection that, in the opinion of the Investigator might cause this study to be detrimental to the patient.
• •History of tuberculosis (TB), irrespective of treatment status. A positive diagnostic TB test at screening defined as a positive QuantiFERON-TB Gold test or T-spot test. In cases where the QuantiFERON or T-spot test is indeterminate, the subject may have the test repeated once, but they will not be eligible for the study unless the second test is negative. In cases where the QuantiFERON or T-spot test is positive, but a follow-up chest x-ray, locally read by a radiologist, shows no evidence of current or previous pulmonary tuberculosis, the subject may be eligible for the study at the discretion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor.
• •QTc \>450 millisecond (msec) or QTc \>480 msec for subjects with bundle branch block at screening.
• •ALT \>2 times upper limit of normal (ULN) and bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent) at screening.
• •Current active or chronic history of liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• •Current or history of renal disease or estimated glomerular filtration rate (GFR) by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) calculation \<60 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) at screening.
• •Hereditary or acquired immunodeficiency disorder, including immunoglobulin deficiency unless subject has a documented history of selective immunoglobulin A (IgA) deficiency.
• •A major organ transplant (example: heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
• •Any planned surgical procedure during the study.
• •A history of malignant neoplasm within the last 5 years, except for adequately treated non-metastatic cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix that has been fully treated and shows no evidence of recurrence.
• •The subject has received treatment with the protocol listed prohibited therapies or changes to those treatments, within the prescribed timeframe.
• •Other medications (including vitamins, herbal and dietary supplements) will be considered on a case-by-case basis, and will be allowed if in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
• •History of alcohol or drug abuse that would interfere with the ability to comply with the study.
• •History of sensitivity to any of the study treatments, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
• •Received a live or attenuated vaccine within 30 days of randomization OR plan to receive a vaccination during the study until 5 half-lives (or 2 days) plus 30 days after receiving GSK2982772.
• •The subject has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives, whichever is longer before the first dose of study medication, or plans to take part in another clinical trial (not inclusive of any UC registry study where no study medication is being administered) at the same time as participating in this clinical trial.
• •Hemoglobin \<10 grams per deciliter (g/dL); hematocrit \<30 percent, white blood cell count \<=3,000 per millimeter cube (mm\^3) (\<=3.0 into 10\^9 per liter); platelet count \<=100,000 per microliter (\<=100 into 10\^9 per liter); absolute neutrophil count \<=1.5 into 10\^9 per liter.
• •Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. As potential for and magnitude of immunosuppression with this compound is unknown, subjects with presence of hepatitis B core antibody (HBcAb) should be excluded.
• •A positive serology for human immunodeficiency virus (HIV) 1 or 2 at screening.
• •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 3 months.
• •Exposure to more than 4 investigational medicinal products within 12 months prior to the first dose.